ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Iovance Biotherapeutics, Inc. ?
1
The company has declared Positive results for the last 4 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD -303.41 MM
- NET PROFIT(HY) Higher at USD -227.82 MM
- ROCE(HY) Highest at -53.16%
2
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -73.25%, its profits have risen by 16.5%
3
Reducing Promoter Confidence
- Promoters have decreased their stake in the company by -0.59% over the previous quarter and currently hold 11.37% of the company
- Promoters decreasing their stake may signify reduced confidence in the future of the business
4
Below par performance in long term as well as near term
- Along with generating -73.25% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Iovance Biotherapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Iovance Biotherapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Iovance Biotherapeutics, Inc.
-74.8%
-0.66
104.79%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
199.88%
EBIT Growth (5y)
-18.25%
EBIT to Interest (avg)
-381.95
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.46
Sales to Capital Employed (avg)
0.11
Tax Ratio
0.86%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
94.26%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.89
EV to EBIT
-0.84
EV to EBITDA
-0.94
EV to Capital Employed
0.80
EV to Sales
1.57
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-95.61%
ROE (Latest)
-48.88%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend19What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -303.41 MM
NET PROFIT(HY)
Higher at USD -227.82 MM
ROCE(HY)
Highest at -53.16%
NET SALES(Q)
At USD 59.95 MM has Grown at 92.73%
RAW MATERIAL COST(Y)
Fallen by -69.05% (YoY
-2What is not working for the Company
CASH AND EQV(HY)
Lowest at USD 661.45 MM
Here's what is working for Iovance Biotherapeutics, Inc.
Net Sales
At USD 59.95 MM has Grown at 92.73%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Net Profit
Higher at USD -227.82 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Operating Cash Flow
Highest at USD -303.41 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Raw Material Cost
Fallen by -69.05% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Depreciation
Highest at USD 11.94 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (USD MM)
Here's what is not working for Iovance Biotherapeutics, Inc.
Cash and Eqv
Lowest at USD 661.45 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
